Rare disease drug development requires knowledge and experience that is not always intuitive or deductible from large population drug development experience. Looking for a Rare Disease drug development expert, both in regulatory and medical affairs, is highly recommended. We’d love to hear from you.
Medical Affairs and Clinical Research
We urge caution when it comes to planning to submit your PRE-IND or IND meeting request so as to avoid common mistakes. We can help with your development plan– contact BBCR to learn more.
November 3rd, 2022 | Medical Affairs and Clinical ResearchEfficiencies in clinical research have become essential in the areas of trial management and trial rescue
October 26th, 2022 | Medical Affairs and Clinical ResearchEvery clinical study has its unique challenges that initially may not have been factored for. Experienced management can help sponsors to address prolonged trial timeline and data quality. Rare Diseases and Precision Medicine require unique approaches to trial execution and data quality. There could be any number of factors that could necessitate a study being […]
BBCR specializes in taking the complexity inherent to the regulatory phase of the approvals and simplifying it by strategizing our support to each client based on product-specific regulatory requirements and functional needs.
October 17th, 2022 | Medical Affairs and Clinical ResearchBBCR can assist clients in the following areas: Regulatory Strategy Thinking ahead during the regulatory process, we avoid unnecessary hurdles in the approvals process. We identify gaps, work through the right strategies for an effective product application, and prepare for label claims. FDA Meeting & Submission Critical to the success of bringing your product to […]
Orphan drug designation provides key incentives of the ODA, including significant tax credits for qualified clinical testing. The BBCR team will empower sponsors with medical insight, ODA application experience, strategic clinical plan, and streamlined trials design.
October 12th, 2022 | Medical Affairs and Clinical ResearchDeveloping drugs with substantial benefits in smaller, molecularly defined, pharmacologically relevant subpopulations of patients with the same clinically recognized disease is increasingly being viewed as a viable pathway for bringing drugs to market.
BBCR supports innovative and repurposing treatments for orphan diseases.
October 4th, 2022 | Medical Affairs and Clinical ResearchDeveloping innovative or repurposing drugs for orphan diseases can be rewarding, but navigating the challenges is not for the faint of heart. Expert guidance is essential in an area where patients are few; a lack of previous studies may hamper progress as you mount an orphan petition and negotiate a clinical plan with the FDA. […]
BBCR provides expert development guidance for Orphan Disease. The BBCR mission is to customize strategies, simplify clinical research, design cost-effective trials, streamline protocols, and create a regulatory roadmap.
September 28th, 2022 | Medical Affairs and Clinical ResearchAs one of the first consultancy teams to streamline clinical trials, BBCR’s boutique consulting team specializes in rare disease and orphan indications dedicated to supporting pharmaceutical innovators, and nurturing each product’s strengths. The BBCR Team provides knowledge in cell, biologics and gene therapies BBCR addresses sponsors’ questions in the ever-changing regulatory environment Clinical strategy for […]
BBCR offers Translational Medicine and Biomarkers Program Consultation to bridge the gap between pre-clinical and early clinical development
September 21st, 2022 | Medical Affairs and Clinical ResearchTranslational medicine is a bridge between pre-clinical and early clinical development (from bench to bedside), creating the foundation for precision medicine in late clinical development. A translational medicine program includes the adoption of biomarkers to mitigate clinical trials risk, identify patient subpopulations, facilitate decision-making, and accelerate drugs’ market approval.
The BBCR mission is to customize strategies, simplify clinical research, design cost-effective trials, streamline protocols, and create a regulatory roadmap. Learn more about our services by visiting bbcrconsulting.com
September 20th, 2022 | Medical Affairs and Clinical ResearchHow we can help The BBCR team provides knowledge in cell, biologics and gene therapies BBCR addresses sponsors’ questions in the ever-changing regulatory environment We offer clinical strategy for orphan diseases and precision medicine RWE can be used to build orphan diseases evidence to support regulatory decisions BBCR serves small and medium sized Biotech Companies, […]
BBCR regularly partners with small and medium sized drug and device biotechnology firms. Our clients are innovators and clinical researchers looking for a more efficient path to approval, and come to us from across the globe. Reach out today to learn more.
September 15th, 2022 | Medical Affairs and Clinical ResearchThe BBCR mission is to simplify clinical research, encourage cost-effective trials, and help innovators navigate through the regulatory process. Small & Medium Sized Biotech Companies currently moving from pre-clinical studies toward clinical trials in need of interim Chief Medical Officer in need of regulatory strategy consultancy in need of preparing a pre-IND, orphan petition, IND, […]
BBCR specializes in strategy and early clinical research services from preclinical through Phase I and POC studies to enable informed, timely decision making for our clients.
August 31st, 2022 | Medical Affairs and Clinical ResearchBBCR Consulting offers clinical, regulatory, translational, and biomarker consulting services that support our clients’ needs. Our process is designed to maximize time and cost efficiencies while mitigating risk. We partner with domestic and international companies. Our mission is to support pharma and biotech companies, and nurture their products’ strengths while improving efficiency and safety.